Contracts & Pricing May 31, 2023 Puerto Rico Medicaid Drug Rebate Program Claims Administrator, TAA Compliance and... 3 Minute Read Updates on US Territory Enrollment Updates, Puerto Rico Medicaid Drug Rebate Program Claims Administrator, TAA Compliance and its Relevance to FSS Agreements, and State Price Transparency Reporting Updates.
Specialty Pharmacy May 15, 2023 Thoughts Following Asembia 2023 Part 1: Exploring the New Pharmacy Landscape 2 Minute Read Channel expert Bill Roth explores how specialty pharmacy has evolved and their take on the current landscape and insights for pharmaceutical organizations.
Contracts & Pricing April 24, 2023 340B Contract Pharmacy Restrictions, M&A Funding in Biotech & FDA Accelerated... 6 Minute Read Updates on 340B Contract Pharmacy Restriction Updates, M&A and Venture Capital Funding in Biotech, and Stricter Accelerated Approval Criteria Proposed for FDA.
Gross-to-Net April 17, 2023 Why Modernize Your Gross-to-Net? 5 Benefits of Pharma Digital Transformation 2 Minute Read In the current pharma landscape, more than 80% of manufacturers still rely on manual processes to accrue, forecast, and report their gross-to-net (GTN) deductions. This is primarily because of...
Government Pricing April 7, 2023 State Pricing Transparency Reporting – Part 2 3 Minute Read Explore the best practice recommendations regarding compliance for SPTR.
Contracts & Pricing March 29, 2023 Updates on MDRP NOTICE Release No. 117, Inflation Reduction Act Guidance... 5 Minute Read Updates on MDRP NOTICE Release No. 117, Inflation Reduction Act, and Operationalizing Medicare Inflationary Rebates.
Launch Readiness March 21, 2023 Perspectives on Pharma Market Access Launch Challenges & Strategy Part 2 9 Minute Read We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.
Gross-to-Net March 6, 2023 5 Pharma Gross-to-Net Questions You Should Be Asking 4 Minute Read Whether manufacturers are entering new therapeutic categories, exploring new indications for a current product, or looking to acquire a new product through acquisition, managing Gross-To-Net can be complex.
Contracts & Pricing February 27, 2023 FDA Set to Apply Orphan-Drug Exclusivity, 2022 Employer Health Benefits Survey... 5 Minute Read Updates on two significant regulatory topics, including the FDA decision on orphan-drug exclusivity regulations and highlights from the Kaiser Family Foundation 2022 Employer Benefits Survey.
Launch Readiness February 7, 2023 Perspectives on Pharma Market Access Launch Challenges & Strategy Part 1 5 Minute Read We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.
